Impact News +++ Here′s Why Bionano Genomics Stock Jumped Today (Fool) +++ BIONANO GENOMICS Aktie -3,36%

GENFIT Aktie

 >GENFIT Aktienkurs 
4.45 EUR    -0.2%    (Tradegate)
Ask: 4.53 EUR / 221 Stück
Bid: 4.46 EUR / 225 Stück
Tagesumsatz: 1000 Stück
Realtime Kurs von 8 bis 22 Uhr!
>GENFIT Performance
1 Woche: +1,1%
1 Monat: +8,6%
3 Monate: +18,7%
6 Monate: -3,8%
1 Jahr: -76,4%
laufendes Jahr: +12,5%
>GENFIT Aktie
Name:  GENFIT S.A. EO -,25
Land:  Frankreich
Sektor:  Gesundheit
ISIN/ Wkn:  FR0004163111 / A0LGJ2
Symbol/ Ticker:  XUP (Frankfurt)
Kürzel:  FRA:XUP, XUP.F, XUP:GR
Index:  -
Webseite:  https://www.genfit.com/
Marktkapitalisierung:  170.18 Mio. EUR
Umsatz:  38.97 Mio. EUR
EBITDA:  -61.86 Mio. EUR
Gewinn je Aktie:  -1.642 EUR
Schulden:  184.64 Mio. EUR
Liquide Mittel:  225.72 Mio. EUR
Umsatz-/ Gewinnwachstum:  -0.10% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  5.88 / 5.51 / -
Gewinnm./ Eigenkapitalr.:  -171.98% / -105.19%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  GENFIT
Letzte Datenerhebung:  13.01.21
>GENFIT Eigentümer
Aktien: 38.8 Mio. St.
f.h. Aktien: 36.89 Mio. St.
Insider Eigner: 6.59%
Instit. Eigner: 4.75%
Leerverk. Aktien: -
>GENFIT Peer Group

 
13.01.21 - 22:12
GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders′ Meeting of January 25, 2021 (GlobeNewswire EN)
 
Lille, France; Cambridge, MA; January 13, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announces the public...
12.01.21 - 20:18
January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders′ vote but quorum not met on first convening (GlobeNewswire EN)
 
Lille, France; Cambridge, MA; January 12, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that the January 13, 2021 Shar...
11.01.21 - 22:15
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire EN)
 
Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the li...
08.01.21 - 18:33
GENFIT Informs its Shareholders of Certain Procedures for the Extraordinary General Meeting of January 13, 2021 (GlobeNewswire EN)
 
Lille, France; Cambridge, MA; January 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today informs its sharehold...
06.01.21 - 22:12
GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event (GlobeNewswire EN)
 
Lille, France; Cambridge, MA; January 6, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that it will be presenting at t...
22.12.20 - 22:12
GENFIT: Renegotiation of the OCEANEs Convertible Bond Terms: Availability of Prospectus Relating to the Admission of New Shares Following Conversion of the OCEANEs (GlobeNewswire EN)
 
Lille (France), Cambridge (Massachusetts, United States), December 22, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases (the “...
07.12.20 - 08:12
GENFIT announces the successful completion of a key milestone in the partial buyback and amendment of its OCEANEs (GlobeNewswire EN)
 
Lille (France), Cambridge (Massachusetts, United States), December 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today an...
30.11.20 - 08:12
GENFIT announces satisfactory preliminary results of its OCEANEs′ partial buyback offer (GlobeNewswire EN)
 
Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today an...
23.11.20 - 08:18
GENFIT Announces Final Terms For Proposed Renegotiation of 2022 OCEANE Convertible Bonds (GlobeNewswire EN)
 
Lille (France), Cambridge (Massachusetts, United States), November 23, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today an...
16.11.20 - 22:12
GENFIT: New Data Presented at AASLD The Liver Meeting Digital Experience™ (GlobeNewswire EN)
 
Lille (France), Cambridge (Massachusetts, United States), November 16, 2020 – GENFIT (Nasdaq and Euronext: GNFT a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today ann...
16.11.20 - 10:43
Genfit reports 9M results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.11.20 - 17:01
Five Prime Therapeutics, Genfit leads healthcare gainers; Aurora Cannabis, The Pennant Group among major losers (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.10.20 - 03:52
GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.09.20 - 23:13
Genfit reports 1H results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.09.20 - 09:31
GNFT Soars On LabCorp Deal, INO′s COVID-19 Vaccine Trial On Partial Hold, FDA Expands Xeljanz Label (RTTNews)
 
Today's Daily Dose brings you news about Abeaona's leadership and Board transitions, GENFIT's deal with LabCorp., FDA hold on Inovio's planned Phase 2/3 Covid-19 vaccine trial, the new CEO of Merck KGaA, and label expansion of Pfizer's blockbus...
28.09.20 - 21:25
Genfit and Lab Corp Partner Up For NASH Liver Test (24/7 Wall St.)
 
Um den gesamten Artikel unter feedproxy.google.com zu lesen, klicken Sie bitte auf die Überschrift...
28.09.20 - 17:04
Genfit, Trxade Group leads healthcare gainers; Abeona Therapeutics, Aquestive Therapeutics among major losers (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.09.20 - 13:10
Genfit up 47% on NASH test deal with LabCorp (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Zitat des Tages: Das Genie ist unter den andern Köpfen, was unter den Edelsteinen der Karfunkel: Er strahlt eigenes Licht aus, während die andern nur das empfangene reflektieren. - Arthur Schopenhauer
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!